Press Release | NeoGenomics Laboratories

December 17, 2012

NeoGenomics Validates and Launches NeoSITE™ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer

NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Fact Sheets

Company Overview

Diagnostic Services

Pharma Services

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients